What we do and who we do it for | Pegasus
March 18, 2016 | Inspiring Healthy Decisions, Integrated communications, Jo Spadaccino, Lisa Bradley, Pegasus, Pegasus showreel, Simon Hackett, This is Pegasus, ThisIsPegasus
We’ve built a new type of health communications consultancy. One that believes in a ‘health first, sector second’ approach. One that connects with every stakeholder. One that blends traditional, digital and social. One that creates all of its content in-house. One that’s transparent and measurable.
Why? Because health conversations are happening everywhere, all of the time. Every day we all make decisions that impact on the quality of our own, and often other people’s, health. From the food we eat, the products we put on our skin, the medicines we take or the routines we create to prevent or manage illness. We might be a healthcare professional, a policy maker, a businessman, a patient, a parent or a combination of all these. We could be in a doctor’s surgery, at home, in the gym, or on the go. Whoever we are, wherever we are, and whatever we are doing, the ability to make healthy decisions, consciously or not, will benefit us as individuals and beyond.
This is a new approach to health communications.
This is Pegasus.
Find out more at info@thisispegasus.co.uk or by calling +44 (0) 1273 712 000.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Inizio Engage CEO Jim Sage featured in pharmaphorum’s “12 Questions” series
Discover Jim Sage’s insights on leadership, industry challenges, and the transformative impact of data, technology, and patient-centric innovation in his latest pharmaphorum “12 Questions” interview.
Reframing the Obesity Conversation: Key Takeaways from ObesityWeek® 2025
As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected...
How DataGateway unified oncology data for real-world insights & market intelligence
Discover how our DataGateway platform unifies fragmented real-world oncology data into a single, validated dataset that delivers deeper insights and faster decision-making.
Inizio launches InConcert™ to transform pre-launch planning through connected intelligence.
Inizio today announced the launch of InConcert™, a new AI-powered data solution designed to accelerate smarter, evidence-led decisions during the critical pre-launch phase of the product lifecycle.
ESMO 2025 highlights: How storytelling, design & emotion are transforming scientific engagement
Discover key insights from ESMO 2025 on how design, emotion, and sustainability are reshaping medical congress experiences. Featuring expert takes from Inizio leaders.
Preparing for ASH 2025: Pharma’s role in hematology innovation
As the global hematology community prepares for the 67th ASH® Annual Meeting and Exposition, Inizio experts share their perspectives on what’s driving the field forward – and how pharma companies...
AI without limits: A smarter, integrated approach to Medical Affairs
At Inizio Medical, we believe AI isn’t replacing Medical Affairs — it’s redefining what’s possible. Our platform, iON.AI™, enhances human expertise, streamlines complex workflows, and strengthens strategic impact through seamless...
What to expect from Obesity Week 2025: Key trends shaping the future of obesity care
Discover how Inizio experts are shaping the future of obesity care—where science, strategy, and innovation unite to advance cardiometabolic health and drive real-world impact.
AI with intent: How Inizio is redefining pharma through precision and partnership
At Fierce Pharma Week, Inizio revealed how the fusion of human expertise and purposeful AI is reshaping pharma communications and driving real-world impact—discover how this human-centered innovation is defining the...
Leading the future of Intelligent Commercialization™: Where proprietary data, tech, and AI meet expert insight
Inizio is leading the way in Intelligent Commercialization™ by uniting proprietary AI-powered platforms, deep scientific expertise, and proven governance to unlock measurable, lasting value at every stage of commercialization.